Thomas A. Samuel

740 total citations
30 papers, 567 citations indexed

About

Thomas A. Samuel is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Thomas A. Samuel has authored 30 papers receiving a total of 567 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Oncology, 12 papers in Pulmonary and Respiratory Medicine and 7 papers in Molecular Biology. Recurrent topics in Thomas A. Samuel's work include Cancer Treatment and Pharmacology (5 papers), Lung Cancer Treatments and Mutations (5 papers) and Breast Cancer Treatment Studies (4 papers). Thomas A. Samuel is often cited by papers focused on Cancer Treatment and Pharmacology (5 papers), Lung Cancer Treatments and Mutations (5 papers) and Breast Cancer Treatment Studies (4 papers). Thomas A. Samuel collaborates with scholars based in United States, Switzerland and Jordan. Thomas A. Samuel's co-authors include Geoffrey I. Shapiro, Michael Levy, Carolyn D. Britten, Cornelia Quadt, Cristiana Sessa, Monica Mita, Udai Banerji, Frauke Schimmöller, Adil Daud and Kapil N. Bhalla and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Oncology and Cancer.

In The Last Decade

Thomas A. Samuel

29 papers receiving 549 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Thomas A. Samuel United States 13 239 167 163 104 77 30 567
Marco Siano Switzerland 15 175 0.7× 153 0.9× 297 1.8× 48 0.5× 41 0.5× 43 639
Mohammad Faranoush Iran 13 171 0.7× 39 0.2× 106 0.7× 71 0.7× 136 1.8× 96 585
L. Peuvrel France 19 280 1.2× 146 0.9× 493 3.0× 152 1.5× 69 0.9× 63 853
Gil Awada Belgium 15 176 0.7× 151 0.9× 450 2.8× 156 1.5× 132 1.7× 58 691
Nikolaos Syrigos Greece 12 187 0.8× 190 1.1× 279 1.7× 76 0.7× 29 0.4× 61 599
Said Baidas United States 12 189 0.8× 125 0.7× 142 0.9× 23 0.2× 83 1.1× 22 442
Elisa Funck‐Brentano France 14 213 0.9× 73 0.4× 377 2.3× 219 2.1× 33 0.4× 36 752
Ali Küpelioğlu Türkiye 15 181 0.8× 86 0.5× 246 1.5× 40 0.4× 28 0.4× 39 578
Victoria Wang United States 12 379 1.6× 129 0.8× 242 1.5× 115 1.1× 76 1.0× 44 805

Countries citing papers authored by Thomas A. Samuel

Since Specialization
Citations

This map shows the geographic impact of Thomas A. Samuel's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thomas A. Samuel with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thomas A. Samuel more than expected).

Fields of papers citing papers by Thomas A. Samuel

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Thomas A. Samuel. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thomas A. Samuel. The network helps show where Thomas A. Samuel may publish in the future.

Co-authorship network of co-authors of Thomas A. Samuel

This figure shows the co-authorship network connecting the top 25 collaborators of Thomas A. Samuel. A scholar is included among the top collaborators of Thomas A. Samuel based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Thomas A. Samuel. Thomas A. Samuel is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Samuel, Thomas A., et al.. (2026). Minimal residual disease in solid tumors: Clinical applications and future directions. Cancer. 132(3). e70286–e70286.
2.
Samuel, Thomas A., et al.. (2023). Impact of COVID-19 on Cancer-Related Care in the United States: An Overview. Current Oncology. 30(1). 681–687. 10 indexed citations
3.
Elimimian, Elizabeth Blessing, Thomas A. Samuel, Hong Liang, et al.. (2021). Clinical and Demographic Factors, Treatment Patterns, and Overall Survival Associated With Rare Triple-Negative Breast Carcinomas in the US. JAMA Network Open. 4(4). e214123–e214123. 25 indexed citations
4.
Sadler, Diego, Chakra P. Chaulagain, Robert J. Cubeddu, et al.. (2020). Practical and cost-effective model to build and sustain a cardio-oncology program. Cardio-Oncology. 6(1). 9–9. 16 indexed citations
5.
Lawrence, Julia, Laura D. Baker, Ernie Balcueva, et al.. (2017). National Institute on Aging /Alzheimer’s Association criteria for Mild Cognitive Impairment applied to chemotherapy treated breast cancer survivors. PubMed. 1(1). 1–19. 7 indexed citations
6.
Daud, Adil, Harriet M. Kluger, Razelle Kurzrock, et al.. (2017). Phase II randomised discontinuation trial of the MET/VEGF receptor inhibitor cabozantinib in metastatic melanoma. British Journal of Cancer. 116(4). 432–440. 52 indexed citations
7.
Lawrence, Jeanette A., Leah Griffin, Ernie Balcueva, et al.. (2015). A study of donepezil in female breast cancer survivors with self-reported cognitive dysfunction 1 to 5 years following adjuvant chemotherapy. Journal of Cancer Survivorship. 10(1). 176–184. 68 indexed citations
8.
Samuel, Thomas A., et al.. (2014). FDG PET/CT in Evaluation of Unusual Cutaneous Manifestations of Breast Cancer. Clinical Nuclear Medicine. 40(1). e63–e67. 4 indexed citations
9.
Sessa, Cristiana, Geoffrey I. Shapiro, Kapil N. Bhalla, et al.. (2013). First-in-Human Phase I Dose-Escalation Study of the HSP90 Inhibitor AUY922 in Patients with Advanced Solid Tumors. Clinical Cancer Research. 19(13). 3671–3680. 119 indexed citations
10.
Hu, Xiao, Kankana Bardhan, Amy V. Paschall, et al.. (2013). Deregulation of Apoptotic Factors Bcl-xL and Bax Confers Apoptotic Resistance to Myeloid-derived Suppressor Cells and Contributes to Their Persistence in Cancer. Journal of Biological Chemistry. 288(26). 19103–19115. 59 indexed citations
11.
Daud, Adil, Harriet M. Kluger, Gerald M. Edelman, et al.. (2013). Activity of cabozantinib in metastatic uveal melanoma: Updated results from a phase II randomized discontinuation trial (RDT).. Journal of Clinical Oncology. 31(15_suppl). 9094–9094. 12 indexed citations
12.
Wells, Jeremy C., et al.. (2013). Tobacco use and race as copredictors of overall survival in patients with breast cancer.. Journal of Clinical Oncology. 31(26_suppl). 20–20. 2 indexed citations
13.
Martin, Lainie P., Mark Kozloff, Roy S. Herbst, et al.. (2012). Phase I study of axitinib combined with paclitaxel, docetaxel or capecitabine in patients with advanced solid tumours. British Journal of Cancer. 107(8). 1268–1276. 21 indexed citations
14.
Kozloff, Mark, Lainie P. Martin, Maciej Krzakowski, et al.. (2012). Phase I trial of axitinib combined with platinum doublets in patients with advanced non-small cell lung cancer and other solid tumours. British Journal of Cancer. 107(8). 1277–1285. 24 indexed citations
15.
Gordon, Michael S., Harriet M. Kluger, Geoffrey I. Shapiro, et al.. (2012). Activity of cabozantinib (XL184) in metastatic melanoma: Results from a phase II randomized discontinuation trial (RDT).. Journal of Clinical Oncology. 30(15_suppl). 8531–8531. 17 indexed citations
16.
Morris, Gloria J., Patricia A. Robinson, Shelly S. Lo, et al.. (2010). Residual Disease After Neoadjuvant Chemotherapy for Breast Cancer. Seminars in Oncology. 37(1). 1–10. 2 indexed citations
17.
Bárcenas, Carlos H., et al.. (2010). Race as an Independent Risk Factor for Breast Cancer Survival: Breast Cancer Outcomes From the Medical College of Georgia Tumor Registry. Clinical Breast Cancer. 10(1). 59–63. 20 indexed citations
18.
Samuel, Thomas A., et al.. (2008). Horns of a Dilemma. Journal of Clinical Oncology. 26(13). 2219–2220. 2 indexed citations
19.
Samuel, Thomas A., Warren Fiskus, Raghavendra Rao, et al.. (2008). Novel aurora kinases-targeted combination therapy for breast cancers. Journal of Clinical Oncology. 26(15_suppl). 14569–14569. 1 indexed citations
20.
Levy, Michael & Thomas A. Samuel. (2005). Management of cancer pain. Seminars in Oncology. 32(2). 179–193. 23 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Marco Siano Breakdown of academic impact, for papers by Mohammad Faranoush Breakdown of academic impact, for papers by L. Peuvrel Breakdown of academic impact, for papers by Gil Awada Breakdown of academic impact, for papers by Nikolaos Syrigos Breakdown of academic impact, for papers by Said Baidas Breakdown of academic impact, for papers by Elisa Funck‐Brentano Breakdown of academic impact, for papers by Ali Küpelioğlu Breakdown of academic impact, for papers by Victoria Wang
Rankless by CCL
2026